ArticleExperimental hematology & oncology2019
Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose.
Stefanie Jilg et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
21 papers cite it
this papercites it